Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
As health care workers, we are ultimately responsible for protecting our patients, ourselves, and the broader community. Wearing PPE for extended periods, as has occurred in the era of COVID-19, can have potentially serious consequences for health care workers. Recognizing occupationally induced skin conditions from PPE, and which of these can be prevented or minimized with proper measures, is critical to help mitigate long-term skin sequelae and maintain compliance.

We would like to thank staff at the American Academy of Dermatology for their logistical and administrative support. We would also like to thank, in particular, Theresa Carbone, BSN, RN, CWOCN, William Falone, MSN, RN, CWON, and Shawn Parsons, MSN, CRNP, CWON, along with the Penn Medicine Wound Care Nursing Collaborative, for their ongoing efforts to educate health care workers and the public on the occupational risks in the era of COVID-19.

Seemal R. Desai, MD, a,b Carrie Kovarik, MD,c Bruce Brod, MD,d William James, MD,e Matthew E. Fitzgerald, DrPh,f Ave Preston, MSN, RN, CWOCN,g and George J. Hruza, MD, MBA h

From the Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, Texas; Innovative Dermatology, Plano, Texas; the Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; the American Academy of Dermatology, Rosemont, Illinois; the Department of Nursing, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and the Department of Dermatology, Saint Louis University, St Louis, Missouri.

Funding sources: None.

Conflicts of interest: Drs Desai, Kovarik, Brod, and Hruza are part of the American Academy of Dermatology Ad Hoc Task Force on COVID-19. Authors James, Fitzgerald, and Preston have no conflicts of interest to declare.

IRB approval status: Not applicable.

Supplemental material available via Mendeley at https://doi.org/10.17632/y578b42s5.1.

Correspondence and reprint requests to: Seemal R. Desai, MD, 5425 W Spring Creek Pkwy, Ste 265, Plano, TX 75024

E-mail: seemald@yahoo.com

Twitter: @SeemalRDesaiMD

REFERENCES

1. Gheisari M, Araghi F, Moravvej H, et al. Skin reactions to non-glove personal protective equipment: an emerging issue in the COVID-19 pandemic [e-pub ahead of print]. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16492. Accessed May 7, 2020.

2. Lan J, Song Z, Xiao Y, et al. Skin damage among health care workers managing coronavirus disease-2019. J Am Acad Dermatol. 2020;82:1215-1216.

3. Foo C, Goon AT, Leow YH, et al. Adverse skin reactions to personal protective equipment against severe acute severe acute respiratory syndrome—a descriptive study in Singapore. Contact Dermatitis. 2006;55:291-294.

4. Donovan J, Kudla I, Holness L, et al. Skin reactions following use of N95 facial masks. Dermatitis. 2007;18:104.

5. National Pressure Injury Advisory Panel (NPIAP). NPIAP position statements on preventing injury with N95 masks. 2020. Available at: https://cdn.ymaws.com/npiap.com/resource/resmgr/position_statements/Mask_Position_Paper_FINALFo.pdf. Accessed May 7, 2020.

6. Beiu C, Mihai M, Popa L, et al. Frequent hand washing for COVID-19 prevention can cause hand dermatitis: management tips. Cureus. 2020;12:e7506.

https://doi.org/10.1016/j.jaad.2020.05.032

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway—inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

To the Editor: Biologic agents have revolutionized psoriasis treatment. However, they are considered “immunosuppressive,” and thus, safety assessments focus on infection, particularly those that are serious or opportunistic, or both. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has focused attention on respiratory track infections (RTIs). The conceptual model of COVID-19 is that immunosuppression early in disease may be harmful, yet may be helpful in “late” severe COVID-19 illness; which may be mediated by a dysregulated hyperimmune response characterized by proinflammatory cytokines including interleukin 17 (IL-17). The effect of IL-17 inhibitors on COVID-19 is unknown, neither the risk of initial infection nor the risk of progression to worse disease. Current understanding of viral immunology suggests that IL-17 is not a dominant cytokine in viral immunity; however, IL-17 is important to mucosal immunity, raising the hypothesis that biologics targeting IL-17 could potentially increase RTI risk.

To test this hypothesis, we calculated a meta-estimate from the placebo-controlled period of phase 3 pivotal IL-17 trials of terms consistent with
RTI of secukinumab, ixekizumab, and brodalumab abstracted from United States Food and Drug Administration prescribing information. RTI is a broad term classified by clinical judgment. The Medical Dictionary for Regulatory Activities (MedDRA), used to classify adverse events (AEs), has multiple terms for RTIs. To assess for RTIs, we summed the number of AEs that are associated with RTIs, divided by the total number of subjects in each study, and then calculated a meta-estimate. We found an increased risk of RTIs in the groups receiving IL-17 inhibitors compared with placebo.

| Study       | Treatment  | Control  | Odds Ratio with 95% CI | Weight (%) |
|-------------|------------|----------|------------------------|------------|
| Brodalumab  | Yes 50     | No 1,446 | 2.14 [1.17, 3.89]      | 23.38      |
|             | Yes 163    | No 1,004 | 1.11 [0.85, 1.45]      | 39.86      |
|             | Yes 112    | No 579   | 1.84 [1.33, 2.55]      | 36.77      |
| Overall     |            |          | 1.56 [1.04, 2.33]      |            |

Random-effects REML model

Fig 1. Meta-estimate of respiratory tract infections (includes “upper respiratory tract infections,” “nasopharyngitis,” “rhinorrhea,” “influenza,” “oropharyngitis,” “pharyngitis,” and “pharyngolaryngeal pain”) from prescribing information adverse events tables. Doses used in this meta-estimate: secukinumab, 300 mg; brodalumab, 210 mg; and ixekizumab, 80 mg every 2 weeks, because these doses are indicated for moderate to severe psoriasis. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the confidence interval (CI). The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. REML, Restricted maximum likelihood.

| Study       | Treatment  | Control  | Odds Ratio with 95% CI | Weight (%) |
|-------------|------------|----------|------------------------|------------|
| Brodalumab  | AMAGINE-1  | Yes 22   | 1.50 [0.76, 2.98]      | 7.32       |
|             | AMAGINE-2  | 103      | 1.25 [0.85, 1.84]      | 14.65      |
|             | AMAGINE-3  | 70       | 0.82 [0.55, 1.24]      | 13.84      |
| Secukinumab | ERASURE    | 40       | 1.73 [1.02, 2.96]      | 10.25      |
|             | FEATURE    | 6        | 0.84 [0.26, 2.67]      | 3.11       |
| Secukinumab | FIXTURE    | 66       | 2.18 [1.39, 3.40]      | 12.66      |
|             | JUNCTURE   | 16       | 1.45 [0.62, 3.40]      | 5.23       |
| Ixekizumab  | UNCOVER-1  | 75       | 1.37 [0.95, 2.00]      | 15.08      |
|             | UNCOVER-2  | 54       | 0.96 [0.58, 1.58]      | 11.02      |
|             | UNCOVER-3  | 29       | 1.36 [0.66, 2.78]      | 6.64       |
| Overall     |            |          | 1.31 [1.05, 1.62]      |            |

Random-effects REML model

Fig 2. Meta-estimate of respiratory tract infections (includes “upper respiratory tract infections,” “viral respiratory tract infections,” “influenza,” “influenza-like illness,” “sinusitis,” “pharyngitis,” “bronchitis,” “cough,” “nasopharyngitis,” “oropharyngeal pain,” and “pneumonia”) from clinicaltrials.gov in the phase 3 randomized control trials that were submitted for United States Food and Drug Administration approval. Doses used in this meta-estimate: secukinumab, 300 mg; brodalumab, 210 mg; and ixekizumab, 80 mg every 2 weeks, because these doses are indicated for moderate to severe psoriasis. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the confidence interval (CI). The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. REML, Restricted maximum likelihood.
(odds ratio, 1.56; 95% confidence interval, 1.04-2.33; Fig 1).

Because prescribing information is not inclusive of all respiratory AEs from the pivotal trials that supported approval of IL-17 inhibitors, we conducted a summary risk estimate using data from the placebo-controlled period of these studies obtained from clinicaltrials.gov. This more detailed analysis yielded similar findings to our meta-estimate of prescribing information data (odds ratio, 1.31; 95% confidence interval, 1.05-1.62; Fig 2). Sensitivity analyses varying the terms analyzed yielded similar findings but with loss of statistical significance.

Evaluating the risk of RTI in clinical trials is difficult because the diagnosis is made clinically without objective testing, and therefore, the etiology of these symptoms, be they viral, bacterial, fungal, or allergic, is unknown. Furthermore, there is substantial variation in the rates of RTIs in the placebo groups across the trials, demonstrating a lack of precision in measuring this outcome. For example, rates of “upper RTI” ranged from 0.0% to 7.44% in the placebo groups evaluated. In addition, owing to variation in reporting of MedDRA terms, the events were unevenly pooled because terms are reported inconsistently. It is also possible that patients may have had more than one RTI event, which could impact our estimates.

These findings highlight the need for more meticulous evaluation of the impact of IL-17 inhibitors on RTIs in the setting of the novel coronavirus pandemic. Nevertheless, our meta-estimate demonstrates a potential safety signal for RTI associated with IL-17 inhibition and supports guidance issued by American Academy of Dermatology that clinicians should use their clinical judgment to continue or discontinue patients on these drugs in patients who have not tested positive or exhibited symptoms of COVID-19 and to discontinue these agents in patients who test positive for COVID-19 symptoms.

Marilyn T. Wan, MBChB, MPH,a Daniel B. Shin, PhD,a Kevin L. Winthrop, MD, MPH,b and Joel M. Gelfand, MD, MSCEac

From the Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvaniaa; the Division of Infectious Diseases and Public Health, Oregon Health and Sciences University, Portland, Oregonb; and the Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvaniac.

Funding sources: Supported in part by a grant (P30-AR0-69589-03) from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Gelfand.

Conflicts of interest: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer, and is a consultant for UCB, AbbVie, Eli Lilly and Company, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche.

IRB approval status: Not applicable.

Correspondence to: Joel M. Gelfand, MD, MSCE, Department of Dermatology, 3400 Civic Center Blvd, Perelman Center for Advanced Medicine, South Tower, Office 730, Philadelphia, PA, 19104

E-mail: joel.gelfand@pennmedicine.upenn.edu

REFERENCES
1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
2. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218.
3. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271-272.
4. Das S, Khader S, Yin and yang of interleukin-17 in host immunity to infection. F1000Res. 2017;6:741.
5. American Academy of Dermatology Association. Guidance on the use of immunosuppressive agents. Available at: https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics. Accessed April 24, 2020.

https://doi.org/10.1016/j.jaad.2020.05.035